Penn’s James M. Wilson, MD, PhD, brings his program’s AAV expertise to collaboration with the developer of the antibody ‘cocktail’ taken by Trump
The Gene Therapy Program at the University of Pennsylvania will partner with Regeneron to explore whether its two-antibody “cocktail” REGEN-COV2 (casirivimab and imdevimab) can prevent COVID-19 infection when delivered as a nasal spray via AAV vectors. [Regeneron Pharmaceuticals]
The University of Pennsylvania's Gene Therapy Program will partner with Regeneron to explore whether its two-antibody “cocktail” REGEN-COV2 (casirivimab and imdevimab) can prevent COVID-19 infection when delivered as a nasal spray via AAV vectors, using expertise developed by GTP and its director James M. Wilson, MD, PhD . . .
